Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H34O5 |
Molecular Weight | 354.481 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC[C@@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
InChI
InChIKey=GMVPRGQOIOIIMI-CHCORRSHSA-N
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16-,17-,19-/m1/s1
Molecular Formula | C20H34O5 |
Molecular Weight | 354.481 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
15-Epiprostaglandin E1 is a synthetic prostaglandin analogue. The activity of the racemic synthetic prostaglandin is approximately one-half that of the naturally occurring compound. 15-Epiprostaglandin E1 is 4% and 6% as potent as PGE1 in contracting the rat uterus and guinea pig ileum. PGA1 is very potent vasodilator and hypotensive agent, whereas its epimer 15-Epiprostaglandin E1 has a little vasodilator or hypotensive effects in anaesthetized dogs. 15-Epiprostaglandin E1 is a non-competitive inhibitor of 15-hydroxyprostaglandin dehydrogenase from human placenta.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1293255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/187123 |
189.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Biological activity of synthetic prostaglandins. | 1969 Mar 29 |
|
Relationship between the chemical structure of prostaglandins and their vasoactivities in dogs. | 1972 Jan |
|
Kinetic studies on a 15-hydroxyprostaglandin dehydrogenase from human placenta. | 1976 Nov |
|
Conformational analysis of prastaglandins. III. Study on active sites and conformation-action relationship. | 1977 Dec |
|
Quantitative determination of alprostadil (PGE) in bulk drug and pharmaceutical formulations by high-performance liquid chromatography. | 1984 Jan 20 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5015041
Unknown
Route of Administration:
Intra-arterial
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:55:07 GMT 2023
by
admin
on
Sat Dec 16 07:55:07 GMT 2023
|
Record UNII |
V2N896SN9V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5283056
Created by
admin on Sat Dec 16 07:55:07 GMT 2023 , Edited by admin on Sat Dec 16 07:55:07 GMT 2023
|
PRIMARY | |||
|
20897-91-0
Created by
admin on Sat Dec 16 07:55:07 GMT 2023 , Edited by admin on Sat Dec 16 07:55:07 GMT 2023
|
PRIMARY | |||
|
V2N896SN9V
Created by
admin on Sat Dec 16 07:55:07 GMT 2023 , Edited by admin on Sat Dec 16 07:55:07 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|